EXT2
Exostosin-2
Also known as: EXT2_HUMAN, SOTV
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q93063
- Gene
- EXT2
- Ensembl
- ENSG00000151348
- Chromosome
- 11
- Canonical length
- 718 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Golgi apparatus
- Secretome location
- Intracellular and membrane
OverviewNCBI Gene
This gene encodes one of two glycosyltransferases involved in the chain elongation step of heparan sulfate biosynthesis. Mutations in this gene cause the type II form of multiple exostoses. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
718 residues, UniProt reviewed canonical sequence.
>Q93063|EXT2
1 MCASVKYNIR GPALIPRMKT KHRIYYITLF SIVLLGLIAT GMFQFWPHSI ESSNDWNVEK
61 RSIRDVPVVR LPADSPIPER GDLSCRMHTC FDVYRCGFNP KNKIKVYIYA LKKYVDDFGV
121 SVSNTISREY NELLMAISDS DYYTDDINRA CLFVPSIDVL NQNTLRIKET AQAMAQLSRW
181 DRGTNHLLFN MLPGGPPDYN TALDVPRDRA LLAGGGFSTW TYRQGYDVSI PVYSPLSAEV
241 DLPEKGPGPR QYFLLSSQVG LHPEYREDLE ALQVKHGESV LVLDKCTNLS EGVLSVRKRC
301 HKHQVFDYPQ VLQEATFCVV LRGARLGQAV LSDVLQAGCV PVVIADSYIL PFSEVLDWKR
361 ASVVVPEEKM SDVYSILQSI PQRQIEEMQR QARWFWEAYF QSIKAIALAT LQIINDRIYP
421 YAAISYEEWN DPPAVKWGSV SNPLFLPLIP PQSQGFTAIV LTYDRVESLF RVITEVSKVP
481 SLSKLLVVWN NQNKNPPEDS LWPKIRVPLK VVRTAENKLS NRFFPYDEIE TEAVLAIDDD
541 IIMLTSDELQ FGYEVWREFP DRLVGYPGRL HLWDHEMNKW KYESEWTNEV SMVLTGAAFY
601 HKYFNYLYTY KMPGDIKNWV DAHMNCEDIA MNFLVANVTG KAVIKVTPRK KFKCPECTAI
661 DGLSLDQTHM VERSECINKF ASVFGTMPLK VVEHRADPVL YKDDFPEKLK SFPNIGSLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EXT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 56 nTPM
Expression across tissuesHPA
Tissue
- placenta: 56 nTPM
- smooth muscle: 45 nTPM
- blood vessel: 37 nTPM
- ovary: 35 nTPM
- endometrium: 35 nTPM
- cervix: 32 nTPM
Single-cell type
- ependymal cells: 101 nCPM
- ocular epithelial cells: 92 nCPM
- early primary spermatocytes: 92 nCPM
- rod photoreceptor cells: 90 nCPM
- brain excitatory neurons: 88 nCPM
- adrenal cortex cells: 86 nCPM
Immune cell
- NK-cell: 18 nTPM
- MAIT T-cell: 17 nTPM
- myeloid DC: 16 nTPM
- gdT-cell: 15 nTPM
- memory CD8 T-cell: 15 nTPM
- eosinophil: 14 nTPM
Brain region
- choroid plexus: 19 nTPM
- hypothalamus: 16 nTPM
- thalamus: 16 nTPM
- white matter: 15 nTPM
- midbrain: 15 nTPM
- pons: 15 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about EXT2.
Disease | AllUniProt
Conditions EXT2 is implicated in, by any mechanism.
- Hereditary multiple exostoses 2 (EXT2) MIM:133701
- Seizures, scoliosis, and macrocephaly/microcephaly syndrome (SSMS) MIM:616682
Disease | GeneticClinVar
233 pathogenic / likely-pathogenic of 1,032 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Exostoses, multiple, type 2
- Seizures-scoliosis-macrocephaly syndrome
- EXT2-related disorder
- Inborn genetic diseases
- Ovarian cancer
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.77
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.64
- DepMap mean gene effect
- -0.23
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to fibroblast growth factor stimulus
- chondrocyte differentiation
- endochondral bone morphogenesis
- fluid transport
- gene expression
- glycosaminoglycan biosynthetic process
- heart contraction
- heparan sulfate proteoglycan biosynthetic process
- heparin proteoglycan biosynthetic process
- mesoderm formation
- multicellular organismal-level water homeostasis
- ossification
- polysaccharide biosynthetic process
- protein N-linked glycosylation
- regulation of blood pressure
- sodium ion homeostasis
- sulfation
- vasodilation
Molecular functions
- glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity
- glucuronosyltransferase activity
- glycosyltransferase activity
- heparan sulfate N-acetylglucosaminyltransferase activity
- metal ion binding
- N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity
- protein heterodimerization activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EXT2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EXT2 as an antibody target. Whether an autoantibody or antibody against EXT2 could matter depends on whether native EXT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EXT2 is annotated as secreted, so native EXT2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label EXT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...